Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
Phase 1/2 Completed
63 enrolled
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Phase 2 Completed
11 enrolled 16 charts
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Phase 2 Completed
40 enrolled 12 charts
Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
Phase 2 Completed
78 enrolled
NRR
Phase 2 Completed
33 enrolled 14 charts
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Phase 1 Completed
28 enrolled
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
Phase 2 Completed
9 enrolled 8 charts
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
Phase 3 Completed
190 enrolled
Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
Phase 2/3 Completed
34 enrolled
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
Phase 1 Completed
115 enrolled
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
Phase 1 Completed
36 enrolled
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin
Phase 1 Completed
63 enrolled
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Phase 2 Completed
11 enrolled